Oscar Health (OSCR) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.10
- EPS estimate
- $0.40
- EPS surprise
- +173.22%
- Revenue surprise
- +1.25%
- Revenue
- $4.8B
- Revenue estimate
- $4.7B
- Reported
- Aug 6, 2026
Oscar Health reported Q2 2026 results on August 6, 2026. Earnings per share were $1.10, 173.22% above the $0.40 estimate. Revenue reached $4.8 billion, 1.25% above the $4.7 billion consensus and the highest in the table. In Q2 2025, Oscar posted a loss of $0.89 per share on $2.9 billion of revenue, so the latest quarter marks a swing to profit and revenue growth of about 66%.
Of the 20 quarters shown, 15 were losses, and each full year from 2022 to 2025 ended with a loss per share: $2.85, $1.20, $0.02 and $1.74. All five profitable quarters fell in the first half of a year: Q1 and Q2 2024, Q1 2025, and Q1 and Q2 2026. The first half of 2026 adds up to $3.17, the strongest half year in the table. Oscar beat the EPS estimate in 11 of the 20 quarters.
Oscar reported third-quarter results between November 6 and November 10 in each of the past five years. That points to early November 2026 for the Q3 2026 report. The third quarter was a loss in each year of the table, so the next report will show whether this year's profits extend past mid-year.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | $0.40 | $1.10 | +173.22% | $4.8B | SEC |
| Q1 2026 | May 6, 2026 | $1.11 | $2.07 | +86.81% | $4.6B | SEC |
| Q4 2025 | Feb 10, 2026 | −$0.89 | −$1.24 | −38.59% | $2.7B | SEC |
| Q3 2025 | Nov 6, 2025 | −$0.54 | −$0.53 | +2.56% | $2.9B | SEC |
| Q2 2025 | Aug 6, 2025 | −$0.81 | −$0.89 | −9.99% | $2.9B | SEC |
| Q1 2025 | May 7, 2025 | $0.79 | $0.92 | +16.06% | $3.0B | SEC |
| Q4 2024 | Feb 4, 2025 | −$0.59 | −$0.62 | −5.07% | $2.3B | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.17 | −$0.22 | −28.35% | $2.4B | SEC |
| Q2 2024 | Aug 7, 2024 | $0.16 | $0.20 | +23.69% | $2.2B | SEC |
| Q1 2024 | May 7, 2024 | $0.27 | $0.62 | +127.94% | $2.1B | SEC |
| Q4 2023 | Feb 7, 2024 | −$0.72 | −$0.66 | +8.65% | $1.4B | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.47 | −$0.29 | +38.62% | $1.4B | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.22 | −$0.07 | +68.40% | $1.5B | SEC |
| Q1 2023 | May 9, 2023 | −$0.06 | −$0.18 | −197.52% | $1.4B | SEC |
| Q4 2022 | Feb 9, 2023 | −$1.14 | −$1.05 | +7.51% | $967.5M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.72 | −$0.91 | −26.56% | $1.3B | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.48 | −$0.53 | −10.72% | $1.4B | SEC |
| Q1 2022 | May 10, 2022 | −$0.21 | −$0.36 | −68.54% | $972.8M | SEC |
| Q4 2021 | Feb 10, 2022 | −$0.98 | −$0.95 | +2.91% | $496.1M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.73 | −$1.02 | −40.42% | $673.5M | SEC |
Quarterly revenue
Frequently asked questions
When did Oscar Health (OSCR) last report earnings?
Oscar Health last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did OSCR beat earnings estimates?
Yes. Oscar Health reported EPS of $1.10 for Q2 2026 against a $0.40 estimate — a 173.22% beat.
How much revenue did OSCR report last quarter?
Oscar Health reported $4.8B in revenue for Q2 2026, against a consensus estimate of $4.7B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.